AI-Driven CDMO Solutions for Advanced Protein Expression and Antibody Drug Development

In this webinar, Dr. Zhu will introduce Creative BioMart's integrated AI platform, which enables accurate 3D structure prediction, affinity maturation, immunogenicity risk assessment, and de novo antibody design — significantly reducing development time and cost. The session will cover our GMP-compliant facilities, scalable mammalian and microbial expression systems, and comprehensive quality control processes. Attendees will learn how our AI-first, dry-wet closed-loop approach achieves high success rates in antibody engineering and membrane protein production, supporting next-generation biotherapeutics.